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Abstract
A membrane receptor, Fas (CD95), and its ligand FasL have been considered as key players in
diabetes pathogenesis. They are known to mediate interactions between β cells and cytotoxic T cells,
which results in apoptotic cell death. We hypothesized that the interruption of Fas-FasL interactions
by suppressing Fas expression in β cells would affect the development of diabetes. The effect of Fas-
silencing siRNA (Fas siRNA) on the diabetes development was evaluated in a cyclophosphamide
(CY)-accelerated diabetes animal model after intravenous administration using a polymeric carrier,
polyethylenimine (PEI). The systemic non-viral delivery of Fas siRNA showed significant delay in
diabetes incidence up to 40 days, while the control mice treated with naked Fas siRNA, scrambled
dsRNA, or PBS were afflicted with diabetes within 20 days. The retardation of diabetes incidence
after the treatment of Fas siRNA may be due to the delayed progression of the pancreatic insulitis.
In this study, the potential use of a non-viral carrier based siRNA gene therapy for the prevention of
type-1 diabetes is demonstrated.
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1. Introduction
Type-1 diabetes, one of the most prevalent autoimmune diseases, results from the destruction
of insulin-producing β cells of the pancreatic islets, mostly leading to absolute insulin
deficiency. Non-obese diabetes (NOD) mice have been popularly used as a model to study
type-1 diabetes since the disease progress of the mice closely resembles that of humans [1,2].
In this animal model, the disease is initiated by infiltration of mononuclear cells into the
pancreatic islets [3,4], which begins after 4–6 weeks of age and develops progressively. In this
stage, only small portion of islet β cells is affected by the attack of the cellular immunity. This
pre-diabetic stage is called insulitis and persists for months, after which overt onset of diabetes
can be observed [5,6]. Both CD4+ and CD8+ T cells play an important role in the initiation
and progress of pathogenesis of type-1 diabetes [7–9]. The recruitment and activation of the
lymphocytes stimulates further secretion of various inflammatory cytokines that could
accelerate the destruction of islet β cells, resulting in systemic insulin depletion. The
development of diabetes in NOD mice is dependent on animal gender, environmental
conditions, diet and other features of each NOD sub-line. Cyclophosphamide (CY), an
alkylating cytostatic drug, is known to promote susceptibility to type-1 diabetes in young pre-
diabetic NOD mice [10]. Acceleration of type-1 diabetes in NOD mice by CY can provide a
convenient synchronization of the disease process. Although the mechanism of action is not
clear, several reports have suggested that CY may cause the destabilization of the local
immune-regulatory balance by temporarily depleting suppressor cells [11,12]. Like in
unmanipulated NOD mice in which type-1 diabetes spontaneously occurs, the death of β cells
caused by apoptosis in the CY-treated accelerated animal model [13,14].
Death of β cells in type-1 diabetes involves multiple mechanisms. One of the major mechanisms
of β cell death is a programmed cell death (apoptosis) by T cells, in which interactions between
Fas (CD95) and its ligand (FasL) contributes significantly to the T cell-mediated β cell
destruction [15,16]. The Fas-FasL interactions activate multiple signaling pathways leading to
apoptotic cell death [17]. The significance of Fas-FasL interactions in the disease development
was initially observed in Fas-deficient NOD mice (lpr/lpr) which failed to induce the disease
and are resistant to adoptive diabetes transfer [18,19]. FasL-deficient NOD mice (gld/gld) were
also protected from either insulitis or diabetes [20]. Prolonged survival of NOD islet graft in
diabetic NOD mice was observed after administration of antibody against FasL (anti-FasL
antibody) [21]. These results suggest that Fas-FasL interactions be involved in at least one (or
more) critical steps in the diabetogenic process. Therefore, interfering Fas-FasL interactions
could be a potential target for the prevention of diabetes.
Gene therapy based on RNA interference (RNAi) has attracted a lot of attention due to its
enormous potential in clinical applications. RNAi, induced by a double-stranded RNA, is a
naturally occurred phenomenon in a cell, by which a gene expression is regulated in a highly
sequence-specific manner at a post-transcriptional level. Small interfering RNA (siRNA) that
can induce a gene-specific RNAi, is a small double stranded RNA sequence composed of 21
to 25 base pairs [22–24]. A number of clinically active siRNA sequences have been screened
by several research groups world-wide. However, the use of siRNA in clinical settings is
limited mainly due to its highly negatively-charged backbone containing phosphodiester
linkages, which are responsible for a poor intracellular uptake through a negatively-charged
plasma membrane and a rapid degradation by extracellular enzymes, respectively [25]. A
number of delivery systems designed to overcome such inherent drawbacks of siRNA has been
suggested for the efficient delivery of therapeutic siRNAs [26]. Delivery systems based on
cationic polymers have been popularly used for the delivery of synthetic siRNA since
polymeric carriers are considered relatively safe from the unexpected adverse events, such as
acute immune responses and systemic cytotoxicity, after repeated administrations for the
treatment of a chronic disease, such as diabetes [25].
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In this study, Fas siRNA was used to induce specific silencing of Fas gene expression in NOD
mice treated with CY for accelerated induction of autoimmune diabetes. Polyethylenimine
(PEI), one of the most widely used polymeric non-viral gene carriers, was employed as a carrier
for delivery of the siRNA in vivo as well as in vitro. The PEI-based delivery of siRNA could
effectively suppress the pancreatic expression of Fas, leading to delayed incidence of insulitis
and CY-induced accelerated diabetes in NOD mice.
2. Materials and methods
2.1. Materials
The synthetic siRNA, annealed duplex of 21-nucleotide RNA modified with 3′-dTdT
overhangs was synthesized and purified by Qiagen Inc (Valencia, CA). The target sequence
for mouse Fas (CD95) and non-silencing negative control were
GUGCAAGUGCAAACCAGAC and AATTCTCCGAACGTGTCACGT, respectively.
Polyethylenimine (PEI, Mw 25,000) and cyclophosphamide (CY) was purchased from Sigma
(St. Louis, MO). Fetal bovine serum (FBS), Dulbecco’s phosphate buffered saline (PBS) and
Dulbecco’s Modified Eagle’s Medium (DMEM) were obtained from Invitrogen (Carlsbad,
CA). Mouse interferon-γ(mIFN-γ) and mouse interleukin-1β (mIL-1β) were from Sigma (St.
Louis, MO). Anti-mouse Fas antibody (Jo2) was purchased from BD PharMingen (San Jose,
CA).
2.2. Formation, characterization and cellular uptake of siRNA/PEI complexes
The formation of siRNA/PEI complexes was confirmed by an electrophoretic mobility shift
assay. Varying amount of PEI and a fixed amount of siRNA (0.3 μg) were separately diluted
in PBS. Prior to use, the complexes were formed by mixing the diluted solutions and allowed
to be stabilized for 20 min at a room temperature. Electrophoresis was performed in 1.5 %
agarose gel with a current of 120 V for 20 min. The retardation of the complexes was visualized
by a UV transilluminator equipped with a CCD image capturing unit (GelDoc, BioRad,
Hercules, CA) after ethidium bromide staining. The size and surface charge of the complexes
were determined by a dynamic light scattering device (ZetaPlus, Brookhaven Instrument Co.
New York, NY) equipped with a He-Ne laser at a wavelength of 632 nm.
2.3. Cell culture and transfection
Mouse insulinoma cells (Min6) were cultured in DMEM supplemented with 15 % FBS and
maintained at 37 °C in a humidified 5 % CO2 atmosphere. For transfection, the cells (5 ×
104) were plated in a 35 mm culture dish. The cells were then incubated 37 °C in a humidified
5 % CO2 atmosphere for 24 h. The cell culture medium was replaced with serum-free medium
prior to the addition of desired siRNA formulations. After 3 h incubation, the transfection
medium was removed and supplemented with fresh growth medium containing 10 % FBS.
The incubation was continued for 6 h and the medium was replaced with new growth medium
containing 10 % FBS and cytokines (1000 U/ml mIFN-γ and 100 U/ml mIL-1β) to stimulate
Fas expression. The cytokine treatment was continued for 18 h before RT-PCR analysis and
induction of apoptosis. Apoptosis was induced by incubating the cytokine-treated cells with
anti-mouse Fas antibody (Jo2, 5 μg/ml) for 24 h.
2.4. Flow cytometry
Flow cytometric method was used to observe cellular uptake of siRNA/PEI complexes. For
flow cytometric analysis, Min6 cells grown in 100 mm dishes were transfected with FITC-
labeled siRNA/PEI complexes as described above. After 4 h of incubation, the cells were
trypsinized, washed three times with cold PBS, and fixed in 1 % paraformaldehyde in PBS at
4 °C for 30 min. The fixed cells were washed two times with cold PBS and subjected to flow
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cytometric analysis to determine cellular uptake (FACS Caliber, Becton-Dickinson, Mountain
View, CA). At least 10,000 events were analyzed to generate each histogram.
2.5. Semi-quantitative RT-PCR and TUNEL assay
To determine the level of Fas expression, total RNA was isolated from the cells using RNeasy®
RNA isolation kit (Qiagen, Valencia, CA), according to the manufacturer’s recommendation.
Complementary DNA (cDNA) strand was synthesized from the RNA using oligo (dT)20 primer
and reverse transcriptase (Invitrogen, Carlsbad, CA) at 50 °C for 30 min. Polymerase chain
reaction was performed using Fas-specific primers (forward: 5′-
GATGCACACTCTGCGATGAA-3′, reverse: 5′-CATGTCTTCAGCAATTCTCGG-3′) for
30 cycles at the following thermal cycling conditions: 94 °C for 30 sec, 60 °C for 30 sec, 72 °
C for 60 sec. Primers for mouse β-actin were 5′-TGGAATCCTGTGGCATCCATGAAAC-3′
(forward) and 5′-TAAAACGCAGCTCAGTAACAGTCCG-3′ (reverse). The PCR products
were separated in a 1 % agarose gel by electrophoresis and visualized by staining with ethidum
bromide under UV illumination.
To visualize apoptosis after the treatment of anti-mouse Fas antibody (Jo2), the terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was carried out using
colorimetric TUNEL assay kit (Promega, Madison, WI), according to the manufacturer’s
instruction. Apoptotic cells stained with diaminobezidine were visualized under a microscope
equipped with CCD camera unit (Olympus, Melville, NY).
2.6. Animals and administration of siRNA
NOD mice (Lt/Jax) were purchased from Jackson Laboratory (Bar Harbor, ME) and were kept
under pathogen-free conditions. To accelerate diabetes, a single dose of CY (250 mg/kg body
weight) was administered i.p. to 7-week-old NOD mice (Day 0). Desired siRNA formulations,
including siRNA/PEI complex (3.3 nmol siRNA, N/P ratio of 10), were injected intravenously
to NOD mice. Blood samples were collected weekly from a tail vein and analyzed by FreeStyle
instant glucometer (Abbott Diabetes Care Inc., Alameda, CA) to determine blood glucose level.
Animals with a blood glucose level above 250 mg/dL were considered diabetic.
2.7. Histological analysis
For histological experiments, mice were sacrificed by cervical dislocation following
anesthetization with methoxyflurane (Schering-Plough Animal Health, Union, NJ) inhalation.
The pancreas was harvested, fixed in 10 % phosphate-buffered formalin solution, and
embedded in paraffin. Sections (5 μm) were cut and stained with hematoxylin and eosin. More
than 20 islets from each pancreas (n=3) were examined using a double blind method. The grade
of insulitis progression was determined by using following grading system [27]: grade 0,
normal islets; grade 1, mononuclear cell infiltration in less than 25 % of the islet; grade 2, 25–
50 % of the islet showing mononuclear cell infiltration; grade 3, over 50 % of the islet showing
mononuclear cell infiltration. Apoptotic cells in the pancreatic islets were stained by TUNEL
assay and visualized by microscopy.
3. Results and discussion
There have been a number of compelling evidences suggesting critical roles of autoreactive
cellular immunity in the apoptotic cell death of islet β cells during the pathogenesis of type-1
diabetes [18,28,29]. Therefore, several strategies for the immunological intervention of the
cellular immunity have been suggested. Diabetic NOD mice having syngeneic islet transplants
could maintain normal blood glucose concentration after the administration of FasL antibody
[21]. The infiltration of mononuclear cells into syngenic islet grafts was also significantly
reduced in the NOD mice apparently due to the apoptotic death of T-cells mediated by the FasL
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antibody. Gene therapy-based immunological intervention for the prevention of diabetes was
also suggested using a plasmid DNA encoding interleukin-4 (IL-4) and interleukin-10 (IL-10).
Systemic administration of the IL-4/IL-10 plasmid DNA formulated with an analogue of poly
(L-lysine), poly(α-[4-aminobutyl]-L-glycolic acid) (PAGA), could result in a significant
reduction of the prevalence of both insulitis and diabetes in NOD mice [30,31]. The
overexpression of IL-4 and IL-10 provide a protective effect and counteract the effect of
pathogenic cytokines such as interferon-γ. The cationic polymer, PAGA, can spontaneously
form nano-size polyelectrolyte complexes with the plasmid DNA in an aqueous solution. In
this study, we hypothesized that the intervention of death receptor-mediated apoptosis by RNA
interference (RNAi) could prevent islet beta cells from apoptotic cell death. Fas siRNA was
selected as a therapeutic candidate for the treatment of type-1 diabetes, since interactions
between Fas and FasL has been considered as a critical event for the initiation of the disease
in NOD mice.
In this study, polyethylenimine (PEI 25 kDa) was employed as a cationic carrier for the delivery
of siRNA. The backbone of PEI has primary, secondary, and tertiary amines with a high density,
which gives the polymer a superior ability for nucleic acid condensation and a hypothetical
proton buffering effect for efficient escape from acidic endosomal compartment [32]. For
decades, PEI 25 kDa has been recognized as a gold standard in non-viral gene therapy due to
its superior properties and reproducibility in transfection experiments. Systemic administration
of PEI/DNA complexes successfully delivered a plasmid DNA to the major organs where
transgene expression was observed [33–35]. In addition, a recent study showed the levels of
inflammatory cytokines such as tumor necrosis factor-α (TNF-α) were much lower after
intravenous administration of PEI/plasmid DNA complexes than the levels of the cytokines
induced by cationic liposome-based lipoplexes, which was independent of the N/P ratio, the
amount of plasmid DNA, or structure and molecular weight of PEI [36]. Similar result was
also found in a study with siRNA/linear PEI complexes [37]. The polymer formed tight
complexes with siRNA above the N/P ratio of 2.5, as observed in an electrophoretic band
mobility shift assay (Figure 1A). Transfection and animal experiments were carried out at the
N/P ratio of 10 at which the hydrodynamic diameter and surface zeta-potential determined by
a light scattering method were 115 ± 23.2 nm and + 23 ± 3.5 mV, respectively. The particle
size was significantly larger than shown in a previous study in which PEI/siRNA complexes
prepared at the N/P ratio of 7.5 was 26 ± 8 nm, as determined by fluorescence correlation
spectroscopy [38]. The significant difference in the particle size may be due to the difference
in analytical methods used in the measurements.
Cellular uptake of siRNA/PEI complexes by Min6 cells was monitored by flow cytometry.
The percentage of the cells gated from an arbitrarily selected region M1 (102<FL1-H<104) for
naked siRNA and siRNA/PEI complex was 11.1 % and 78.1 %, respectively (Figure 1B),
suggesting that cellular uptake of siRNA could be significantly improved by forming complex
with PEI.
Significance of Fas siRNA as a specific RNA interference inducer was evaluated by the
transfection of the siRNA into mouse insulinoma cells (Min6), followed by the addition of
mIFN-γ and mIL-1β that stimulates Fas expression. It was reported that mIFN-γ and mIL-1β
increase the level of Fas presented on the cell surface [39]. The formulation of Fas siRNA/PEI
complexes effectively suppressed Fas mRNA transcripts, as determined by semi-quantitative
RT-PCR (Figure 2A). In contrast, scrambled siRNA/PEI complexes did not show any silencing
effect on Fas expression, suggesting the sequence specificity of the Fas siRNA. The anti-
apoptotic effect of Fas siRNA was observed by using TUNEL assays (Figure 2B). Fas-mediated
apoptosis was induced by incubating the cells with anti-Fas antibody (Jo2) after the cytokines
treatment. The cells transfected with Fas siRNA/PEI complexes demonstrated significant
suppression of anti-Fas antibody-mediated apoptosis, compared to control groups that include
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naked siRNA and scrambled siRNA/PEI complexes. The results suggest the anti-apoptotic
effect of Fas siRNA comes from the specific silencing of Fas expression at the post-
transcriptional level.
The effect of Fas gene silencing in the pancreas by Fas siRNA on the incidence of insulitis and
diabetes was further studied in a CY-induced accelerated diabetes model. Diabetes could be
induced in young pre-diabetic NOD mice within 4 weeks by a single intraperitoneal
administration of CY (250 mg/kg). Apparently, CY triggers the acute diabetes by affecting
immunoregulatory T cells. It was also reported that the intraperitoneal (i.p.) administration of
CY to NOD mice makes islet infiltrating lymphocytes more pathogenic by increasing the
number of lymphocytes producing IFN-γ [40]. In order to observe protective effect of Fas
siRNA in vivo, Fas siRNA formulated with PEI was administered to the NOD mice through
a tail vain concomitantly to CY i.p. injection (Day 0). An additional intravenous injection of
the Fas siRNA/PEI formulation was given to the NOD mice on day 6. Glucose levels were
monitored weekly using blood samples collected from the tail vain. As shown in Figure 3, the
overt onset of diabetes was significantly delayed by the treatment of Fas siRNA up to 40 days
after CY injection. In contrast, most of the control mice treated with naked Fas siRNA,
scrambled siRNA (Sc siRNA), or PBS were afflicted with diabetes within 20 days. It should
be noticed that blood glucose concentration of the Fas siRNA-treated mice also gradually
increased with time, but the increment rate was much slower than the control groups (data not
shown). In this study, animals with a blood glucose level above 250 mg/dL were considered
diabetic. Naked Fas siRNA showed only limited preventive effect on the development of
diabetes. This may be due to the inherent instability of siRNA in the biological fluid. The
stability of the siRNA during systemic circulation could be significantly improved by forming
tight polyelectrolyte complexes with PEI. Recent publication showed PEI could dramatically
improve the in vivo stability of siRNA, leading to successful therapeutic effect of siRNA
through systemic application [41].
In order to investigate the effect of systemic Fas siRNA treatment on the progress of insulitis
in the CY-treated NOD mice, the complexes formed from the interaction between Fas siRNA
and PEI were intravenously administered (on day 0 and 6) to 7-week old NOD mice that had
been treated with CY (i.p.) on day 0. After 7 and 14 days, the mice were sacrificed. The
pancreata were harvested and stained with hematoxylin and eosin for the evaluation of insulitis.
The result showed that 60 % of the observed islets were intact in the group treated with Fas
siRNA/PEI complexes after 14 days (Figure 4C and D). In contrast, less than 15 % remained
intact in control groups treated with naked siRNA. Furthermore, in the Fas siRNA treatment
group, the majority of the islets infiltrated by mononuclear cells were scored as peripheral
insulitis (grade 1). However, over 60 % of islets in the control groups showed severe insulitis
(grade 3) after 14 days. Only a few mononuclear cell infiltrations into the islets was detected
in all test groups before the day of CY treatment (data not shown). This result suggests that the
administration of Fas siRNA/PEI complexes could efficiently suppress the recruitment and
infiltration of mononuclear cells.
TUNEL staining of the histological sections demonstrated that most of the islets did not
undergo apoptosis in the Fas siRNA/PEI treatment group after 14 days (Figure 5). Together
with the H&E staining result, this suggests systemic administration of Fas siRNA/PEI
complexes could effectively suppress the incidence of diabetes by reducing insulitis and
apoptosis of islet cells.
Pancreatic expression profiles of Fas mRNA transcript in the CY-treated NOD mice were
observed using RT-PCR. The Fas siRNA/PEI complexes were administered to the CY-treated
NOD mice via tail vein (on day 0 and 6). After 7 and 14 days, mRNA was isolated from the
pancreas and analyzed by RT-PCR using Fas-specific primers. The pancreatic expression of
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Fas transcript was only detected in CY-treated mice and not in the mock (PBS) treated mice
(Figure 6A). Significant suppression of Fas expression was observed in the mice treated with
Fas siRNA/PEI complexes on day 7 (Figure 6A and 6B). However, the control groups treated
with sc siRNA/PEI and PBS failed to silence Fas expression. Naked Fas siRNA exhibited much
lower suppression of Fas expression, compared to the Fas siRNA/PEI formulation.
Interestingly, on day 14, the Fas mRNA band disappeared in both treatment and control groups
(Figure 6B).
One possible reason of this result could be the rapid clearance of Fas-expressing cells via
interactions with mononuclear cells having FasL on their membrane. Another possible
explanation is that it may take a while for the restoration of the immune-regulatory balance
between suppressor and pathogenic regulatory cells, which was temporarily disrupted by the
CY treatment. Although the mechanism of CY-induced diabetes in NOD mice is not fully
understood, a previous result observed dramatic increase in an IFN-γ secretion level in NOD
spleenocytes after CY injection [40]. The over-expression of IFN-γ can be supported by another
study using a microarray analysis, in which a marked increase in expression of IFN-γ and its
related genes was observed 3 days after CY administration [42]. The acute increase of IFN-γ
expression may induce Fas expression on islet cells [15,43]. The suppressor cells such as Th2-
like cells secreting protective IL-4 and IL-10 seems to be either more sensitive to CY (therefore,
preferentially eliminated) or regenerated at a slower rate [11], while regulatory cells secreting
pathogenic IFN-γ are relatively resistant to CY-induced depletion [40]. The results suggest the
potential role of Fas in the early stage of diabetes. In addition, when Fas siRNA/PEI complexes
were administered to CY-treated NOD mice in the late phase of the disease development (on
day 9 and 15), the retardation of diabetes onset was not observed (Figure 7). This could support
the hypothetical role of Fas in the early stage of diabetic pathogenesis. Critical role of Fas-
FasL interactions for the initiation of type-1 diabetes was discussed in a previous report [44].
In this study, PEI-mediated delivery of Fas siRNA could successfully silence the target gene
expression, leading to the delayed incidence of type-1 diabetes in CY-treated NOD mice.
However, the biodistribution of siRNA/PEI complexes in the pancreatic islets could not be
clearly observed. Recent studies also failed to clearly show the pancreatic distribution of radio
isotope-labeled siRNA/PEI complexes following intravenous administration [45,46]. This may
be due to the characteristics of pancreatic islets. Pancreatic islet is highly vascularized since
the islets attract endothelial cells by secreting vascular endothelial growth factor (VEGF) to
induce neo-angiogenesis, which promotes β-cell proliferation and islet growth [47]. In addition,
islet blood flow is very high and islet capillaries are fenestrated, which allows rapid glucose
uptake and metabolite exchange by islet cells [48]. The high blood flow and the fenestrated
structure of islet capillaries may facilitate the localization of siRNA/PEI complexes in the islets.
However, the average number of islets in mouse pancreas is only 500 ~ 800, which only make
up 1~2 % of the total pancreas cells [49]. Thus, despite the potential accumulation of probe-
labeled siRNA/PEI complexes in the islets, the probe signal may not be high enough to reach
a detection limit of a device. Therefore, it should be considered as a next step to design a gene
delivery system which can specifically target islet beta-cells, which may provide the enhanced
therapeutic effect of the siRNA and the opportunity of resolving the pancreatic biodistribution
of siRNA/carrier complexes.
4. Conclusion
Although polymer-based non-viral gene carriers still have a room for improvement in terms
of gene transduction efficiency, they have an advantage over its viral counterparts for the
treatment of chronic diseases, such as diabetes. Synthetic carriers can be repeatedly
administered for an extended period of time without safety concerns, such as a host immune
stimulation and a risk of unexpected genomic insertion. In this study, we demonstrated that
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non-viral gene therapy based on RNAi-mediated gene silencing could effectively retard the
progress of insulitis and type-1 diabetes in CY-treated NOD mice. Further studies including
the development of a gene delivery system that can target pancreatic islet β-cells, Fas siRNA
gene therapy in a spontaneous diabetes model in NOD mice, and the elucidation of detailed
mechanisms concerning the role of Fas in early phase of diabetic pathogenesis should be carried
out as next steps for the diabetes gene therapy.
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Fig. 1.
Electrophoretic mobility shift assay of siRNA/PEI complexes at various polymer/siRNA N/P
ratios (A) and cellular uptake of siRNA/PEI complexes by Min6 cells (B), determined by flow
cytometry.
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Fig. 2.
Suppression of Fas expression (A) and anti-apoptotic effect (B) of Fas siRNA/PEI complexes
in Min6 cells. Fas expression was induced by treating the cells with 1000 U/ml mIFN-γ and
100 U/ml mIL-1β. Apoptosis was induced by incubating the cytokine-treated cells with anti-
mouse Fas antibody (Jo2, 5 μg/ml).
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Fig. 3.
Preventive effect of Fas siRNA/PEI ceomplexes on CY-induced diabetes in NOD mice.
Diabetes was induced by injecting a single dose of CY (250 mg/kg body weight) (Day 0) prior
to the administration of indicated formulations. Animals with a blood glucose level above 250
mg/dL were considered hyperglycemic (n = 15).
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Fig. 4.
Suppression of insulitis after systemic administration of Fas siRNA/PEI complexes in CY-
treated NOD mice. The mouse pancreata were harvested on day 7 (A, B) and day 14 (C, D)
and stained with hematoxylin and eosin. Arrows indicate mononuclear cell infiltrations. More
than 20 islets from three animals (n=3) were examined to determine insulitis grade (B, D) based
on the grading system described in Materials and Methods.
Jeong et al. Page 14
J Control Release. Author manuscript; available in PMC 2011 April 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 5.
Prevention of apoptosis in pancreatic islets after intravenous injection of Fas siRNA/PEI
complexes. Cellular apoptotic event in pancreatic islets (inside the marked boundary) was
visualized by TUNEL staining.
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Fig. 6.
(A) Effect of CY treatment on pancreatic Fas expression. (B) Suppression of Fas expression
after the intravenous administration of Fas siRNA/PEI complexes in CY-treated NOD mice
(n=3).
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Fig. 7.
Effect of intravenous administration of Fas siRNA/PEI complexes in the late phase of diabetes
development on diabetes incidence in CY-treated NOD mice (n = 10).
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